CJC-1295 and Ipamorelin Peptide Blend is a research formulation combining two well-characterized peptide compounds that are frequently examined together in growth hormone–associated signaling studies. In laboratory research settings, this combination is utilized to explore GHRH-related pathway engagement alongside ghrelin receptor–associated signaling dynamics within controlled, non-human experimental systems. When evaluated in combination, CJC-1295 and Ipamorelin are studied for their complementary interaction with growth hormone–linked regulatory frameworks, allowing researchers to examine signal timing, pathway coordination, and endocrine feedback architecture without implying applied or therapeutic outcomes. Research models focus on receptor-mediated signaling behavior, temporal pathway responsiveness, and system-level endocrine communication, rather than direct biological effects. This dual-peptide research approach provides a structured framework for investigating growth hormone axis signaling, endocrine pathway integration, and cellular communication networks in non-human laboratory environments. Due to their distinct but related receptor interactions, the CJC-1295 and Ipamorelin blend remains a widely used tool in endocrinology-focused research examining GH-associated signaling architecture under controlled experimental conditions. This material is supplied exclusively for laboratory research and analytical use. It is not intended for human use, animal use, diagnostic use, or therapeutic application. Summary of Characteristics Attribute CJC-1295 Ipamorelin Chemical Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu Aib-His-D-2-Nal-D-Phe-Lys-NH₂ Molecular Formula C165H269N47O46 C38H49N9O5 Molecular Weight 3,647.19 g/mol 711.85 g/mol Other Known Titles GHRH-Associated Research Peptide, GRF 1-29 Analog (Research) Ghrelin Receptor–Associated Research Peptide, NNC 26-0161
